Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other Non-Current Liabilities (2016 - 2020)

Historic Other Non-Current Liabilities for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Q4 2020 value amounting to $1000.0.

  • Syndax Pharmaceuticals' Other Non-Current Liabilities fell 8000.0% to $1000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $1000.0, marking a year-over-year decrease of 8000.0%. This contributed to the annual value of $1000.0 for FY2020, which is 8000.0% down from last year.
  • Syndax Pharmaceuticals' Other Non-Current Liabilities amounted to $1000.0 in Q4 2020, which was down 8000.0% from $2000.0 recorded in Q3 2020.
  • In the past 5 years, Syndax Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $312000.0 in Q1 2018 and a low of $1000.0 during Q4 2020
  • In the last 5 years, Syndax Pharmaceuticals' Other Non-Current Liabilities had a median value of $148000.0 in 2017 and averaged $143350.0.
  • In the last 5 years, Syndax Pharmaceuticals' Other Non-Current Liabilities skyrocketed by 11081.08% in 2018 and then crashed by 9775.64% in 2019.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Other Non-Current Liabilities stood at $288000.0 in 2016, then grew by 7.64% to $310000.0 in 2017, then crashed by 56.13% to $136000.0 in 2018, then plummeted by 96.32% to $5000.0 in 2019, then crashed by 80.0% to $1000.0 in 2020.
  • Its Other Non-Current Liabilities stands at $1000.0 for Q4 2020, versus $2000.0 for Q3 2020 and $3000.0 for Q2 2020.